



# Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS.

Administrative Office: 101, Shiv Shakti Industrial Estate, Sir. M. V. Road, Andheri (E), Mumbai-400 059

Registered Office: 4801/B & 4802/A, G.I.D.C Industrial Estate, Ankleshwar-393 002.

CIN: L2430GJ1976PLC008738

## EXTRACT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED 31<sup>ST</sup> MARCH, 2017

(₹ in Lacs)

PARTICULARS	Quarter ended			Current Year ended	Previous period ended
	31-Mar-17	31-Dec-16	31-Mar-16	31-Mar-17	31-Mar-16
	(Audited)	(Unaudited)	(Audited)	12 Month (Audited)	9 Month (Audited)
1 Total Income from operations (Net)	3,060.24	3,190.02	3,461.76	11,658.25	13,040.90
2 Net Profit/(Loss) from ordinary activities after Tax	2.15	(235.48)	(1677.90)	(550.92)	(408.99)
3 Net Profit/(Loss) for the period after Tax & Extra ordinary items	2.15	(253.70)	(1677.90)	(569.13)	(408.99)
4 Paid Up Equity Share Capital (Face value of ₹ 10/- share)	2,204.00	2,204.00	2,204.00	2,204.00	2,204.00
5 Reserve excluding Revaluation Reserve as shown in the balance sheet of previous year				1061.72	1527.19
6 Earning per share in ₹ (before Extraordinary items) of ₹ 10 each					
Basic	0.82	(1.24)	(5.45)	(2.09)	1.65
Diluted	0.82	(1.24)	(5.45)	(2.09)	1.65
7 Earning per share in ₹ (after Extraordinary items) of ₹ 10 each					
Basic	0.82	(1.32)	(5.45)	(2.17)	1.65
Diluted	0.82	(1.32)	(5.45)	(2.17)	1.65

### Notes:

- The above is an extract of the detailed format of Quarterly/Half yearly Financial results filed with the stock Exchange under Regulation 33 of the SEBI (Listing and other disclosure requirements) Regulations, 2015. The full format of Quarterly/Half yearly Financial results are available on the Stock Exchange Websites. ([www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com))
- The above Audited Financial results has been reviewed by the Audit Committee and approved and taken on record by the Board of Directors of the Company at their meeting held on 29<sup>th</sup> May, 2017.
- The figures for the last quarter ended 31<sup>st</sup> March, 2017 being balancing figures between audited figures in respect of the Year ended 31<sup>st</sup> March, 2017 and published year to date figures upto 31<sup>st</sup> December, 2016.
- The Statutory Auditors of the Company have carried out the audit on consolidated basis of the financial results for the Year ended 31<sup>st</sup> March, 2017.
- Audited financial results for the Year ended 31<sup>st</sup> March, 2017 have been consolidated with that of Lyka BDR International Ltd., Lyka Healthcare Ltd., and Lyka Exports Ltd., for the year ended 31<sup>st</sup> March, 2017
- During the Quarter the Holding Company has charged to Profit & Loss Account ₹ 81.84 lacs being depreciation on revalued assets.
- Exceptional items consist of:

Sr. No.	Particulars	Year ended 31 <sup>st</sup> March, 2017 (₹ In lacs)
a)	Quality Claim	217.32
b)	Loss on sale of Fixed Assets	11.20
c)	Loss on sale of Investments	1.61
d)	Irrecoverable claim/Advance written off	54.89
e)	VAT Paid under Amnesty Scheme	128.63
	TOTAL	413.65

- Tax expenses comprises of deferred tax assets.
- The Company has one Single Segment "Pharmaceuticals".
- Figures for previous year have been regrouped/rearranged wherever necessary, to conform to the relevant current year classification.

For LYKA LABS LIMITED

N. I. GANDHI

(DIN: 00021530)

Chairman & Managing Director

Mumbai  
29-May-17